Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BicycleTx Limited
Maastricht University Medical Center
Memgen, Inc.
Incyte Corporation
Exelixis
Compugen Ltd
Tempest Therapeutics
Nektar Therapeutics
Nektar Therapeutics
Incyte Corporation
Bristol-Myers Squibb
MultiVir, Inc.
Celgene